Atropine & Pralidoxime Chloride Injector, Single Dose Auto- Injectors

Background
The Strategic National Stockpile (SNS) of the U.S. Department of Health and Human Services (HHS) Office of the Administration for Strategic Preparedness and Response (ASPR) has a requirement for Atropine & Pralidoxime Chloride Injector, Single Dose Auto-Injectors. The goal of this contract is to ensure the availability of these critical medical supplies for emergency preparedness and response.

Work Details
The contract requires the delivery of Atropine & Pralidoxime Chloride Injector, Single Dose Auto-Injectors. The specifications include:
- The product must be FDA approved.
- It must be Trade Agreement Act (TAA) compliant.
- Packaging and case configuration must adhere to the specifications outlined in the Statement of Work (SOW), including details on case dimensions, package configuration (e.g., number of auto-injectors per case, number of rows per pallet), types of injectors utilized, pallet layout, and material intended for packing and transporting.
- Delivery, packaging, and shipping conditions must meet or exceed the requirements identified in the SOW.
- Offerors must provide a detailed delivery schedule that aligns with the SOW's requirements.

Period of Performance
The anticipated period of performance will begin on or before September 30, 2024, with three ordering periods:
1. Base Delivery Period – Period 1: September 2024 – September 2025
2. Ordering Period 2: September 2025 – September 2026
3. Ordering Period 3: September 2026 – September 2027

Place of Performance
The products will be delivered to various SNS locations as specified in the contract.